Monopar Therapeutics Stock Forecast
NASDAQ: MNPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:39 AM ET
MNPR analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$129.92+59.14%
- Strong buy 4
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Monopar Therapeutics (2026-10-08), 11 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $129.92, with a high estimate of $145.00 and a low estimate of $119.00. The average target implies upside of 59.1% from the current price of $81.64.
The spread between the highest and lowest targets is 21.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MNPR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 33% |
| Buy | 7 | 58% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $119.00 | +45.76% |
| Average target | $129.92 | +59.14% |
| High target | $145.00 | +77.61% |